Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2018-10-24 Board/Management Inform…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo appoints Joseph DeFeo as new CFO
Board/Management Information Classification · 1% confidence The document is a press release announcing a specific change in senior management: the appointment of Joseph DeFeo as the new Chief Financial Officer (CFO) and the departure of the previous CFO. This directly aligns with the definition for Board/Management Information (MANG), which covers 'Announcement of changes in the company's board of directors or senior management.' The document is short and focused solely on this personnel change.
2018-10-24 English
Orexo utser Joseph DeFeo som ny CFO
Board/Management Information Classification · 1% confidence The document is a press release announcing a change in senior management: the appointment of Joseph DeFeo as the new Chief Financial Officer (CFO). This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is short and structured as a formal announcement, not a comprehensive report like a 10-K or IR.
2018-10-24 Swedish
Orexo utser valberedning och offentliggör finansiell kalender 2018/2019
AGM Information Classification · 1% confidence The document is a press release ("Pressmeddelande") dated October 8, 2018. It primarily announces two things: the appointment of the Nomination Committee (Valberedning) for the upcoming 2019 Annual General Meeting (AGM) and the publication of the financial calendar for 2018/2019. The text explicitly mentions the AGM date (April 11, 2019) and details related to shareholder proposals for the AGM. Since it deals with the preparation and scheduling for the Annual General Meeting, the most fitting category is AGM Information (AGM-R). Although it announces the financial calendar, the core focus is the AGM process setup. It is not the AGM presentation itself, nor is it a full report (10-K, IR) or a proxy statement (DEF 14A/PSI).
2018-10-08 Swedish
Orexo appoints Nomination Committee and publishes financial calendar 2018/2019
Report Publication Announcement Classification · 1% confidence The document is a press release announcing two main items: the appointment of a Nomination Committee ahead of the 2019 Annual General Meeting (AGM) and the publication of the financial calendar for 2018/2019. The text explicitly mentions the AGM date and procedures for submitting proposals for the meeting. While it discusses the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI). It is an announcement regarding corporate governance structure (Nomination Committee) and future reporting dates. Since it deals with the structure related to the AGM and governance, and also publishes a calendar, it is a general corporate announcement. However, the most specific element related to a future event is the AGM announcement. Given the options, this document primarily serves to announce corporate governance updates (Nomination Committee) and future meeting/reporting dates. It is not a full report (10-K, IR), an earnings release (ER), or a specific director dealing report (DIRS). Because it details the composition and function of the Nomination Committee, which is a key governance body related to the AGM, and announces the AGM date, it fits best under general corporate governance or a specific announcement category. Since it is a press release announcing governance structure changes related to the AGM, and the AGM itself is a major event, I will check if there is a better fit. It is not a DEF 14A (Remuneration) or PSI (Proxy Solicitation). It is a general announcement. Given the focus on the Nomination Committee and AGM logistics, it is a corporate governance/meeting related announcement. Since there isn't a perfect 'Corporate Governance Announcement' code, and it is a press release announcing future events and committee appointments, it falls under a general regulatory filing/announcement category. However, the content heavily revolves around the upcoming AGM and the committee responsible for board nominations. If we consider the AGM context, AGM-R is for presentations *at* the meeting. This is an announcement *before* the meeting about the committee that prepares for it. Given the structure and content, it is a general regulatory announcement, but the focus on the AGM makes AGM-R a possibility if interpreted broadly, but RPA (Report Publication Announcement) is usually for announcing the release of a *report*. Since this is a press release announcing governance structure and a calendar, RNS (Regulatory Filings) is the most appropriate fallback for a general, non-specific corporate announcement that doesn't fit the other specific categories like ER, 10-K, or DIV. I will re-evaluate based on the AGM context. The document is about setting up the AGM process. It is not a DEF 14A (Remuneration) or PSI (Proxy). It is a press release announcing governance structure. I will classify it as RNS as it is a general corporate announcement/press release that doesn't fit the specific report types.
2018-10-08 English
Orexo wins appeal against Actavis on Zubsolv patent in the US
Legal Proceedings Report Classification · 1% confidence The document is a press release announcing the outcome of a patent litigation case ('Orexo wins appeal against Actavis on Zubsolv patent in the US'). This concerns a significant legal matter involving intellectual property protection. Based on the provided definitions, the category 'Legal Proceedings Report (Code: LTR)' is the most appropriate fit, as it covers updates on significant lawsuits and regulatory actions. The document is not a financial report (10-K, IR, ER), a management change (MANG), or a general regulatory announcement (RNS), but a specific update on litigation.
2018-09-10 English
Orexo vinner överklagandet mot Actavis avseende Zubsolvs patent i USA
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a significant legal victory for Orexo regarding the patent validity of Zubsolv in the USA against Actavis. It details the court ruling, the implications for patent exclusivity until 2032, and includes a quote from the CEO. Crucially, it announces a conference call for the next day to discuss the news. This structure—a brief announcement of a material event (legal outcome) followed by details and a call invitation—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement of a material event required for public disclosure (as stated at the end: "Denna information är sådan information som Orexo AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning"), and it is not a specific financial report, management discussion, or director dealing report, the most appropriate general category is Regulatory Filings (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) as it contains the substance of the news, not just a notice that a report is available.
2018-09-10 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.